STOCK TITAN

Orchestra BioMed (OBIO) director reports 4,238 RSU tax-withholding shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. director Chris Cleary reported a Form 4 transaction involving 4,238 shares of common stock on August 12, 2026. The shares were withheld by the company solely to satisfy tax withholding obligations upon vesting of restricted stock units, with no shares sold in the market. Following this withholding, Cleary directly holds 29,153 common shares.

Positive

  • None.

Negative

  • None.
Insider Cleary Chris
Role Director
Type Security Shares Price Value
Tax Withholding Common Stock, par value $0.0001 per share F1 4,238 $4.42 $19K
Holdings After Transaction: Common Stock, par value $0.0001 per share — 29,153 shares (Direct)
Footnotes (1)
  1. F1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.
Shares withheld for taxes 4,238 shares Common stock withheld on August 12, 2026 to satisfy tax withholding obligations on vesting RSUs
Withholding price per share $4.42 per share Value used for the 4,238 common shares withheld for tax obligations
Shares held after transaction 29,153 shares Directly owned Orchestra BioMed common shares after the tax-withholding transaction
restricted stock units financial
"in connection with vesting of restricted stock units ("RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"to satisfy tax withholding obligations in connection with vesting of restricted"
Payment of tax liability by delivering or withholding securities financial
"transaction_code_description": "Payment of tax liability by delivering or withholding"

FAQ

What insider transaction did Orchestra BioMed (OBIO) report for Chris Cleary?

Director Chris Cleary reported 4,238 shares of Orchestra BioMed common stock withheld on August 12, 2026 to cover tax obligations from vesting RSUs, with no market sale occurring.

Was there a market sale of OBIO shares in Chris Cleary’s latest Form 4?

No market sale occurred. 4,238 shares were withheld by the issuer solely to satisfy tax withholding obligations related to vesting restricted stock units, as disclosed in the footnote.

How many Orchestra BioMed (OBIO) shares does Chris Cleary hold after this transaction?

After the tax-withholding transaction, Chris Cleary directly holds 29,153 shares of Orchestra BioMed common stock, according to the reported post-transaction ownership figure on the Form 4.

What was the price used for the OBIO tax-withholding shares on Chris Cleary’s Form 4?

The tax-withholding disposition used a price of $4.42 per share for the 4,238 common shares withheld to satisfy Cleary’s tax obligations on vesting RSUs.

What does transaction code F mean in the OBIO Form 4 for Chris Cleary?

Transaction code F indicates payment of tax liability by delivering or withholding securities. For Chris Cleary, this reflects issuer share withholding for taxes on vesting RSUs, not an open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cleary Chris

(Last)(First)(Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE

(Street)
NEW HOPE PENNSYLVANIA 18938

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share08/12/2026F(1)4,238D$4.4229,153D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.
/s/ Andrew Taylor, Attorney-in-Fact08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)